Many pathogens, including HIV, SARS-CoV-2, influenza, rotavirus, and cholera, infect the host through mucosal surfaces and thus are thought to require engagement of both systemic and mucosal branches of the immune system, using a combination of immunoglobulin G (IgG) and IgA antibodies, for effective management and protection (1, 6, 7). This evidence concerns the gene CD79A and vibrio infectious disease.